---
title: "药捷安康核心产品替恩戈替尼发表探索性临床结果"
description: "药捷安康宣布其核心产品替恩戈替尼在美国进行的胆管癌探索性临床 2 期结果发表在《柳叶刀，胃肠病和肝病学》。研究显示，替恩戈替尼可克服 FGFR2 融合阳性胆管癌患者对 FGFR 抑制剂的耐药性，并在其他 FGFR 基因改变的患者中显示抗肿瘤活性。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/270025011.md"
published_at: "2025-12-17T14:13:56.000Z"
---

# 药捷安康核心产品替恩戈替尼发表探索性临床结果

> 药捷安康宣布其核心产品替恩戈替尼在美国进行的胆管癌探索性临床 2 期结果发表在《柳叶刀，胃肠病和肝病学》。研究显示，替恩戈替尼可克服 FGFR2 融合阳性胆管癌患者对 FGFR 抑制剂的耐药性，并在其他 FGFR 基因改变的患者中显示抗肿瘤活性。

药捷安康－B(02617.HK) 公布，近日，公司核心产品替恩戈替尼在美国开展的针对胆管癌的探索性临床 2 期结果在《柳叶刀，胃肠病和肝病学》发表。替恩戈替尼可克服 FGFR2 融合阳性胆管癌患者对 FGFR 抑制剂的获得性耐药，并在其他 FGFR 基因改变的胆管癌患者中显示出抗肿瘤活性。

在这项 2 期、开放标签、多中心研究中，符合条件的胆管癌患者包括携带 FGFR2 融合且对 FGFR 抑制剂存在原发性或获得性耐药的患者，或存在其他 FGFR 基因改变的患者，以及 FGFR 野生型患者。

### Related Stocks

- [02617.HK - 药捷安康-B](https://longbridge.com/zh-CN/quote/02617.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib | Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib | [Link](https://longbridge.com/zh-CN/news/276393466.md) |
| Extensively Drug-resistant Salmonella Outbreak Linked To Moringa Powder Capsules | The CDC has reported a multi-state outbreak of extensively drug-resistant Salmonella linked to Rosabella brand moringa p | [Link](https://longbridge.com/zh-CN/news/276049869.md) |
| 13:03 ETBelay Diagnostics Announces the Validation of Summit™ 2.0 Comprehensive Genomic Profile Assay in Cerebrospinal Fluid (CSF) | Belay Diagnostics has announced the validation of its Summit™ 2.0 Comprehensive Genomic Profile assay for cerebrospinal  | [Link](https://longbridge.com/zh-CN/news/276259162.md) |
| Abbisko Advances FGFR4 Inhibitor Irpagratinib With First U.S. Patient Dosed in Global HCC Trial | Abbisko Cayman Limited has dosed the first U.S. patient in a global Phase I trial of irpagratinib, an FGFR4 inhibitor fo | [Link](https://longbridge.com/zh-CN/news/275528457.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/zh-CN/news/276051793.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。